Gallic acid downregulates matrix metalloproteinase-2 (MMP-2) and MMP-9 in human leukemia cells with expressed Bcr/Abl

被引:46
作者
Chen, Ying-Jung [1 ]
Chang, Long-Sen [1 ,2 ]
机构
[1] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 804, Taiwan
[2] Kaohsiung Med Univ, Dept Biotechnol, Kaohsiung, Taiwan
关键词
AP-1; Bcr; Abl; Gallic acid; JNK1; MMP-2; MMP-9; MEDIATED DEATH PATHWAY; PROSTATE-CANCER CELLS; HUMAN-MELANOMA CELLS; EPIGALLOCATECHIN-3-GALLATE EGCG; TRANSCRIPTIONAL ACTIVATION; ANGIOGENIC FACTORS; UP-REGULATION; U937; CELLS; KAPPA-B; APOPTOSIS;
D O I
10.1002/mnfr.201200167
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Scope The aim of the present study was to explore the signaling pathways associated with gallic acid induced matrix metalloproteinase-2 (MMP-2)/MMP-9 downregulation in human leukemia K562 cells. Methods and results Unlike the insignificant effect on human Bcr/Abl-negative leukemia U937 cells, gallic acid attenuated invasion of human Bcr/Abl-positive leukemia K562 cells with characteristic of decreased protein expression and mRNA levels of MMP-2 and MMP-9. Gallic acid induced beta-TrCP upregulation evoked Bcr/Abl degradation in K562 cells, while overexpression of Bcr/Abl attenuated gallic acid induced MMP-2/MMP-9 downregulation. Overexpression of Bcr/Abl restored the levels of phospho-ERK and phospho-Akt but not JNK phosphorylation in gallic acid treated K562 cells. Gallic acid treatment repressed Akt/ERK-mediated c-Fos phosphorylation and JNK1-mediated ATF-2 phosphorylation. c-Jun inactivation was mediated through gallic acid induced Akt/ERK and JNK inactivation. Knockdown of c-Fos, c-Jun, and ATF-2 by siRNA and luciferase promoter assay reflected that c-Jun/ATF-2 and c-Jun/c-Fos were, respectively, responsible for MMP-2 and MMP-9 expression in K562 cells. Chromatin immunoprecipitating assay showed that gallic acid reduced the binding of c-Jun/ATF-2 and c-Jun/c-Fos with promoter region of MMP-2 and MMP-9 genes, respectively. Conclusion Our data indicate that MMP-2 and MMP-9 downregulation in gallic acid treated K562 cells are mediated through suppression of JNK1-mediated c-Jun/ATF-2 and Akt/ERK-mediated c-Jun/c-Fos pathways, respectively.
引用
收藏
页码:1398 / 1412
页数:15
相关论文
共 71 条
[1]   Gallic acid causes inactivating phosphorylation of cdc25A/cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces apoptosis in human prostate carcinoma DU145 cells [J].
Agarwal, Chapla ;
Tyagi, Alpna ;
Agarwal, Rajesh .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (12) :3294-3302
[2]   The AP-1 site and MMP gene regulation: What is all the fuss about? [J].
Benbow, U ;
Brinckerhoff, CE .
MATRIX BIOLOGY, 1997, 15 (8-9) :519-526
[3]   Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells [J].
Chandra, J ;
Hackbarth, J ;
Le, S ;
Loegering, D ;
Bone, N ;
Bruzek, LM ;
Narayanan, VL ;
Adjei, AA ;
Kay, NE ;
Tefferi, A ;
Karp, JE ;
Sausville, EA ;
Kaufmann, SH .
BLOOD, 2003, 102 (13) :4512-4519
[4]   Gallic acid, a major component of Toona sinensis leaf extracts, contains a ROS-mediated anti-cancer activity in human prostate cancer cells [J].
Chen, Huei-Mei ;
Wu, Yang-Chang ;
Chia, Yi-Chen ;
Chang, Fang-Rong ;
Hsu, Hseng-Kuang ;
Hsieh, Ya-Ching ;
Chen, Chih-Chen ;
Yuan, Shyng-Shiou .
CANCER LETTERS, 2009, 286 (02) :161-171
[5]   Naja nigricollis CMS-9 enhances the mitochondria-mediated death pathway in adaphostin-treated human leukaemia U937 cells [J].
Chen, Ying-Jung ;
Wang, Jeh-Jeng ;
Chang, Long-Sen .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2011, 38 (11) :755-763
[6]  
Crowe David L., 1999, Neoplasia (New York), V1, P368, DOI 10.1038/sj.neo.7900041
[7]   Jun N-terminal kinase 1 mediates transcriptional induction of matrix metalloproteinase 9 expression [J].
Crowe, DL ;
Tsang, KJ ;
Shemirani, B .
NEOPLASIA, 2001, 3 (01) :27-32
[8]   Matrix metalloproteinase inhibition by green tea catechins [J].
Demeule, M ;
Brossard, M ;
Pagé, M ;
Gingras, D ;
Béliveau, R .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 2000, 1478 (01) :51-60
[9]  
Demeule Michel, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P441, DOI 10.2174/1568011023353930
[10]   Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia [J].
Donato, NJ ;
Wu, JY ;
Stapley, J ;
Lin, H ;
Arlinghaus, R ;
Aggarwal, B ;
Shishodin, S ;
Albitar, M ;
Hayes, K ;
Kantarjian, H ;
Talpaz, M .
CANCER RESEARCH, 2004, 64 (02) :672-677